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Introduction: Understanding oncogenes and tumor suppressor 
genes expression patterns is essential for characterizing lung can-
cer pathogenesis. We have previously demonstrated that mGprc5a/
hGPRC5A is a lung-specific tumor suppressor evidenced by inflam-
mation-mediated tumorigenesis in Gprc5a-knockout mice. The 
implication of GPRC5A in human lung cancer pathogenesis, includ-
ing that associated with inflammatory chronic obstructive pulmonary 
disease (COPD), a risk factor for the malignancy, remains elusive. 
Methods: We sought to examine GPRC5A immunohistochemi-
cal expression in histologically normal bronchial epithelia (NBE) 
from lung disease-free never- and ever-smokers (n = 13 and n = 18, 
respectively), from COPD patients with (n = 26) and without cancer 
(n = 24) and in non-small cell lung cancers (NSCLCs) (n = 474). 
Quantitative assessment of GPRC5A transcript expression in airways 
(n = 6), adjacent NBEs (n = 29) and corresponding tumors (n = 6) 
from 6 NSCLC patients was also performed.
Results: GPRC5A immunohistochemical expression was signifi-
cantly lower in tumors compared to uninvolved NBE (p < 0.0001) and 
was positively associated with adenocarcinoma histology (p < 0.001). 
GPRC5A airway expression was highest in lung disease-free NBE, 
decreased and intermediate in NBE of cancer-free COPD patients 
(p = 0.004) and further attenuated and lowest in epithelia of COPD 
patients with adenocarcinoma and SCC (p < 0.0001). Furthermore, 
GPRC5A mRNA was significantly decreased in NSCLCs and corre-
sponding NBE compared to uninvolved normal lung (p = 0.03). 
Conclusions: Our findings highlight decreased GPRC5A expression 
in the field cancerization of NSCLC, including that associated with 
lung inflammation. Assessment of the use of GPRC5A expression as 
a risk factor for NSCLC development in COPD patients is warranted. 
KEY WORDS: Field cancerization, Chronic obstructive pulmonary 
disease, Non–small-cell lung cancer,  g-protein coupled receptor 
family C, group 5, member A, gene expression.
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Lung cancer, the majority of which is non–small cell lung cancer (NSCLC), is the leading cause of deaths in the 
United States and worldwide.1 The high mortality associ-
ated with lung cancer is in part because of late diagnosis after 
regional or distant spread of the disease.2 Improved clinical 
management of NSCLC is tightly linked to the identification 
of new effective early biomarkers that can spear novel strate-
gies for early detection, prevention, and treatment.2,3
The majority (85%) of diagnosed NSCLC cases are 
attributable to cigarette smoking.4,5 Auerbach et al. 6 earlier 
showed that tobacco carcinogen exposure causes multifocal 
and clonal histopathological changes in the airway epithelia 
of smokers, suggestive of a field cancerization in the lung. In 
addition, cigarette smoking perpetuates inflammation through-
out the smoking-exposed airway epithelia of heavy smokers,7 
which was suggested, to lead to onset of lung cancer develop-
ment.8 Chronic obstructive pulmonary disease (COPD) of the 
lung is an inflammatory condition that is, like lung cancer, 
causally linked to cigarette smoking9,10 and is a major cause 
of mortality in the United States.11 Moreover, preinvasive lung 
cancer lesions are common (approximately 50%) in airways 
of COPD patients.12 Importantly, although phenotypically 
healthy smokers comprise a significant population at risk for 
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lung cancer,5,7 COPD increases lung cancer risk by 4.5-fold, 
more than either age or quantity of smoking.11,13,14 In addi-
tion, 33% of patients with mild-to-moderate COPD eventually 
die because of lung cancer burden.11 Although smoking is the 
main cause of both diseases, only 10% to 15% of smokers 
develop COPD and/or lung cancer, suggesting that other fac-
tors, including genetic variation and expression, may differ 
across individuals in response to cigarette smoke.4,5,9,10 It is 
plausible to assume that understanding common expression 
patterns between both diseases for subsequent identification 
of biological markers that explain risk of disease onset and/or 
progression will favorably promote the clinical management 
of COPD-associated lung cancer.11
Our group has previously demonstrated that loss of 
G-protein coupled receptor, family C, group 5, member A 
(mGprc5a/hGPRC5A), exemplified by the Gprc5a-knockout 
mouse model, leads to chronic inflammation and spontaneous 
lung tumor development.15,16 However, the expression of this 
tumor suppressor in human lung NSCLCs, including those 
associated with inflammatory conditions such as COPD, is 
unknown. We investigated the immunohistochemical expres-
sion of GPRC5A in a large series of NSCLC histological tis-
sue specimens and in normal bronchial epithelia (NBE) from 
lung-disease–free individuals, COPD patients and from COPD 
patients with lung cancer and its transcript expression in inde-
pendent resected normal epithelia and corresponding tumors. 
Our findings reveal marked reduced GPRC5A expression in 
human NSCLC and in the histologically normal field can-
cerization associated with COPD and lung cancer. Our study 
pinpoints to a potential role of this tumor suppressor in the pro-
gression of COPD-associated NSCLC, which warrants further 
studies to assess its use as a risk marker for this disease.
MATERIALS AND METHODS
NSCLC Tissue mMcroarrays and Normal 
Bronchial Epithelial Specimens
Tissue microarrays (TMAs) used in this study com-
prised 474 surgically resected NSCLC tumor specimens (308 
adenocarcinomas, 166 squamous cell carcinomas [SCCs]) 
collected under an Institutional Review Board protocol and 
archived as formalin-fixed paraffin-embedded (FFPE) speci-
mens in the University of Texas Specialized Program of 
Research Excellence thoracic tissue bank at the University 
of Texas M.D. Anderson Cancer Center. Clinicopathological 
features of the NSCLC patients examined are summarized in 
Table 1. TMAs were prepared with a manual tissue arrayer 
(Advanced Tissue Arrayer ATA100, Chemicon International, 
Temecula, CA) using 1-mm diameter cores in triplicate for 
tumors, as described previously.17 Histological sections 4 µm 
in thickness were then prepared for subsequent immunohisto-
chemistry analysis. FFPE specimens of NBE from 50 patients 
with COPD with forced expiratory volume in 1 second/forced 
vital capacity ratio of 70% or less, a smoking history of 30 or 
more pack-years, and collected at Baylor college of Medicine 
(Houston, TX) were included in the study, including 24 can-
cer-free cases and 26 cases with NSCLC. In addition, NBE 
specimens from never smokers (n = 13) and ever smokers 
(n = 18) without lung cancer and with no or mild airway 
obstruction status were analyzed.
Immunohistochemical Analysis
Polyclonal antirabbit antibodies raised against human 
GPRC5A were generated by peptide synthesis and site-
directed carrier conjugation using keyhole limpet hemocyanin 
as a custom service by Zymed Laboratories Inc. (South 
San Francisco, CA). The synthetic peptide (cysteine)-
PSPYKDYEVKKEGS-COOH, corresponding to amino 
acids 344–357 in the human GPRC5A C-terminus, was 
covalently linked to keyhole limpet hemocyanin via an added 
cysteine residue, and polyclonal antipeptide antibodies were 
prepared in rabbits. Sera were confirmed to contain high-titer 
antibodies against the specific peptide using enzyme-linked 
immunosorbent assays. TMAs and the histologic sections (4 
µm thick) of surgical resected specimens were deparaffinized 
and hydrated, and antigen retrieval was performed using a 
decloaker with Dako target retrieval system at a pH of 6.0 (Dako 
North America, Inc., Carpinteria, CA). Intrinsic peroxidase 
activity was blocked by 3% methanol and hydrogen peroxide 
for 12 minutes and serum-free protein block (Dako) was used 
for 30 minutes for blocking nonspecific antibody binding. 
Slides were then incubated with the antibodies against human 
GPRC5A (1:200 dilution) at 4°C overnight. After three washes 
in Tris-buffered saline, slides were incubated for 30 minutes 
with Dako Envision + Dual Link at room temperature. After 
three additional washes, slides were incubated with Dako 
chromogen substrate for 5 minutes and were counterstained 
with hemotoxylin for another 5 minutes. FFPE whole-section 
specimens, except for the omission of the primary antibodies, 
were used as negative controls. The intensity and extent of 
cytoplasmic and nuclear GPRC5A immunostaining were 
evaluated using a light microscope (magnification, × 20) 
TABLE 1.  Clinicopathological Features of NSCLC Patients in 
Tissue Microarray Sets Used in the Study
Covariate Levels n (%)
Sex Female 240 (50.6)
Male 234 (49.4)
Histology Adenocarcinoma 308 (65.0)
Squamous cell carcinoma 166 (35.0)
Stage I 302 (63.7)
II 86 (18.1)
III or IV 86 (18.1)
Grade* Well 36 (10.4)
Moderate 193 (55.9)
Poor 116 (33.6)
Smoking status Current 178 (37.6)
Former 229 (48.3)
Never 67 (14.1)
Tobacco history No 67 (14.1)
Yes 407 (85.9)
*Information on differentiation grade was available in a subset of NSCLCs analyzed.  
NSCLC, non–small-cell lung cancer. 
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independently by two pathologists (JF and IIW). GPRC5A 
immunoreactivity was mainly cytoplasmic, which was 
quantified using a four-value intensity score (0, none; 1, weak; 
2, moderate; and 3, strong) and the percentage (0–100%) of 
the extent of reactivity. A final cytoplasmic expression score 
was obtained by multiplying the intensity and reactivity 
extension values (range, 0–300).
GPRC5A Transcript Expression in Resected 
NSCLC Specimens and Adjacent Airway 
Epithelia 
GPRC5A mRNA expression was assessed in ever-smoker 
NSCLCs and their uninvolved normal lung parenchyma tis-
sues as well as in NBE collected by brushing of multiple 
corresponding airways from the same lobectomy- and pneu-
monectomy-resected specimens. Tumor tissues from six ever-
smoker NSCLCs and normal lung specimens (n = 6) as well as 
NBE by brushings (n = 29) from the same patients were obtained 
under an Institutional Review Board approved protocol in which 
specimens were collected from patients who had signed letters 
of consent. NBE were collected from multiple adjacent to tumor 
airways by brushing each site independently using Cytosoft 
cytology brushes (Cardinal Health, Dublin, OH). Parallel 
brushes were used for touch-prep for cytological assessment by 
pan-cytokeratin staining, which revealed epithelial content more 
than 90%. Normal histology was determined by hematoxylin 
and eosin staining. Brushes were immediately placed in Qiazol 
lysis reagent (Qiagen, Valencia, CA) and stored in −80°C until 
further processing. NSCLC and normal lung specimens were 
shaved for histological assessment of percentage of tumor con-
tent and malignant cells and for corresponding RNA isolation. 
Total RNA from all samples was purified using the miRNeasy 
kit (Qiagen) according to the manufacturer’s instructions. RNA 
quantity was determined using the NanoDrop spectrophotome-
ter, (Thermo Scientific, Wilmington, DE), and quality was deter-
mined by analysis of RNA integrity with Agilent Bioanalyzer 
2000 (Agilent Technologies, Santa Clara, CA).
Quantitative-Real Time Polymerase  
Chain Reaction 
Total RNA (150 ng) was reverse-transcribed using 
the high-capacity RNA-to-cDNA kit (Life Technologies, 
Carlsbad, CA) according to the manufacturer’s instructions. 
Quantitative real-time polymerase chain reaction (PCR) was 
performed using TaqMan® (Applied Biosystems, Foster City, 
CA) gene expression assays for GPRC5A (Hs00173681_m1) 
and beta-actin (ACTB) (Hs99999903_m1) primers (Life 
Technologies) on a 7900HT Fast-Real-Time PCR System 
(Life Technologies) according to the manufacturer’s instruc-
tions. All samples were done in triplicates and normalized to 
ACTB. Relative quantification was calculated using the com-
parative cycle threshold method as previously described.18
Statistical Analysis 
Summary statistics, including frequency tabulation, 
means, standard deviations, median, and range, were given 
to describe patient characteristics. Wilcoxon rank sum test 
or Kruskal–Wallis test was used to compare GPRC5A 
immunohistochemical expression between two levels or among 
more than two levels, when appropriate. General linear model 
was applied to test the difference of GPRC5A expression across 
NBE from COPD- and cancer-free never and ever smokers, 
cancer-free COPD patients, as well as NBE from patients with 
both COPD and cancer. Repeated measures analysis was used to 
determine significance of GPRC5A transcript variation across 
matched NSCLCs, airways, and uninvolved normal lung. All 
statistical tests were two-sided, and p values of 0.05 or less were 
considered to be statistically significant. Statistical analysis was 
performed with standard statistical software, including SAS 
Release 9.1.3 for Windows and S-Plus 8.0 for Windows.
RESULTS
GPRC5A Immunohistochemical Expression in 
Human NSCLC
We have previously demonstrated that mGprc5a/
hGPRC5A is a lung-specific tumor suppressor evidenced 
by spontaneous tumor development in mice with knockout 
of this gene as well as loss of the transformed phenotype in 
malignant NSCLC cell lines after GPRC5A overexpression.16 
We sought to examine the immunohistochemical expression 
patterns of GPRC5A tumor suppressor in NSCLC, which is 
unknown, and its association with clinicopathological fea-
tures of the disease, including the two major histologic types 
examined, adenocarcinoma and SCC. The clinicopatho-
logical characteristics of the NSCLC patients from which 
FFPE tumor specimens were analyzed are detailed in Table 
1. Representative photomicrographs of GPRC5A immuno-
histochemical expression in human lung adenocarcinoma 
(left) and SCC (right) are depicted in Figure 1A. GPRC5A 
immunoreactivity was mainly cytoplasmic. GPRC5A 
expres sion was significantly lower in the adenocarcinomas 
(n = 308; mean, 48.91 ± 36; median, 41.67; minimum, 0; 
maximum, 180) and SCCs (n = 166; mean, 23.47 ± 22.79; 
median, 18.33; minimum, 0; maximum, 110) examined com-
pared with the uninvolved normal bronchial epithelia (mean, 
164.52 ± 34.04; median, 160; minimum, 100; maximum, 
230) from lung- disease–free smokers and never smokers 
(p < 0.0001) (Fig. 1B). Moreover, GPRC5A immunohisto-
chemical expression was significantly lower in SCCs com-
pared with that in adenocarcinomas (p < 0.0001) (Fig. 1B). 
We then correlated GPRC5A with other clinicopathological 
features for all NSCLCs. Notably, GPRC5A expression was 
significantly increased in NSCLC tumor specimens from 
never smokers (n = 67) (mean, 53.94 ± 39.94; median, 40; 
minimum, 0; maximum, 163.33) compared with ever smokers 
(n = 407) (mean, 37.71 ± 32.65; median, 30; minimum, 0; max-
imum, 180) (p = 0.001) (Fig. 1C). GPRC5A expression was 
also significantly different among never, former and current 
smoker NSCLCs (p = 0.003) (Fig. 1D). In addition, GPRC5A 
expression was significantly positively associated with well-
differentiated tumor grade in a subset of NSCLC tumors 
(n = 346) examined with available grade information (p = 0.004) 
(Fig. 1E). It is important to note that when we examined each 
histology type separately, there were no statistically significant 
1750 Copyright © 2012 by the International Association for the Study of Lung Cancer
Fujimoto et al. Journal of Thoracic Oncology  •  Volume 7, Number 12, December 2012
correlations between GPRC5A expression and patient’s smok-
ing history and status, and tumor-differentiation grade.
GPRC5A Immunohistochemical Expression 
in NBE from COPD Patients
We have previously shown that loss of mGprc5a/
hGPRC5A tumor suppressor leads to chronic-inflammation–
mediated prosurvival signaling and transformation of 
nonmalignant lung epithelial cells.15 The relevance of 
GPRC5A expression to human NSCLC pathogenesis, 
including that associated with COPD, a chronic inflammatory 
condition and risk factor for lung cancer, remains elusive. In 
light of the strong association between inflammation, COPD 
and NSCLC,10,11 we sought to examine the expression of 
GPRC5A NBE in COPD-associated adenocarcinoma and 
SCC. GPRC5A expression was assessed in histological tissue 
specimens of NSCLC and NBE, including those from lung 
cancer-free COPD and from NSCLC patients. Representative 
photomicrographs of GPRC5A immunohistochemical 
staining in the different NBE are depicted in Figure 2A. 
GPRC5A immunoreactivity seemed to be highest in NBE 
from lung-disease–free never and ever smokers, successively 
significantly decreased in NBE of COPD patients who are 
cancer-free, and lowest in NBE of patients with both COPD 
and adenocarcinoma or SCC (Fig. 2B). A general linear model 
demonstrated a significant gradual decrease of GPRC5A 
expression from NBE of disease-free never smokers to 
NBE from patients with COPD and adenocarcinoma or 
SCC (p < 0.0001) (Fig. 2B). The mean (177.31 ± 30.66) and 
median (195; minimum, 130; maximum, 220) of GPRC5A 
expression in NBE of lung-disease–free never smokers 
were higher than that of smokers (mean, 155.28 ± 34.15, 
median, 147.5; minimum, 100; maximum, 230) although 
the differences were not statistically significant (Fig. 2B). 
Moreover, GPRC5A expression was significantly higher 
in NBE of lung-disease–free smokers relative to NBE in 
cancer-free COPD patients (mean, 85.48 ± 53.55, median, 
72.88; minimum, 20; maximum, 211) (p = 0.007), which in 
turn was significantly higher compared with the expression 
in NBE from COPD patients with adenocarcinoma (mean, 
48.15 ± 52.84, median, 35; minimum, 0; maximum, 170) 
(p < 0.0001) or SCC (mean, 32.24 ± 34.9, median, 12.5; 
minimum, 0; maximum, 101.69) (p < 0.0001) (Fig. 2B). 
Furthermore, although GPRC5A expression was lower in 
NBE of COPD patients with SCC compared with those 
with COPD and adenocarcinoma, the difference was not 
statistically significant (Fig. 2B). These findings suggest that 
reduced expression of the GPRC5A tumor suppressor may 
be implicated in the pathogenesis of NSCLC associated with 
inflammatory COPD.
FIGURE 1.  GPRC5A immunohistochemical expression in NSCLC histological tissue specimens. A, Representative photomi-
crographs of GPRC5A immunohistochemical expression in lung adenocarcinoma (left) and SCC (right) observed under a light 
microscope at a magnification of 20 ×. Bars, 100 µm. B, Box-plots depicting differences in GPRC5A immunohistochemical 
expression among NBE, Adeno, and SCCs. C, Box-plots depicting GPRC5A expression based on tobacco history (never ver-
sus ever smokers), (D), smoking status (never, former and current), and (E), differentiation grade (well, moderate, and poor). 
p values based on the Wilcoxon rank sum test and Kruskal–Wallis test. GPRC5A, G-protein coupled receptor family C, group 
5, member A; NSCLC, non–small-cell lung cancer; SCC, squamous cell carcinomas; NBE, normal bronchial epithelia; Adeno, 
adenocarcinomas.
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We then examined GPRC5A expression in epithelial 
cells from different compartments of the lung (bronchial, 
bronchiolar and alveolar epithelia and cells). GPRC5A 
expression was statistically significantly lower in bronchi 
and bronchioles from cancer-free COPD patients (p < 0.005) 
and patients with both COPD and SCCs or adenocarcinomas 
(p < 0.0001) compared with lung-disease–free never smokers 
(Supplementary Table 1, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A334). In contrast, GPRC5A 
expression in alveolar compartment remained high (score 
average 172.2–261.5) in all groups of cases examined, and 
there were no statistically significant differences based on 
COPD status (Supplementary Table 1, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A334).
GPRC5A Expression in Smoker NSCLC Field 
Cancerization
Our previous findings on GPRC5A tumor-suppressive 
function15,16,19 as well as our current observation on significant 
and progressive reduced expression of this tumor suppressor in 
NBE from lung cancer-free COPD patients and patients with 
NSCLC, prompted us to probe whether GPRC5A expression 
exhibits a field cancerization pattern in NSCLC. We sought 
FIGURE 2.  Reduced GPRC5A expression in the sequential pathogenesis of COPD-associated NSCLC. A, Representative 
photomicrographs of GPRC5A immunohistochemical expression in NBE from disease-free never and ever smokers (upper 
left and upper right, respectively) and in NBE from cancer-free COPD patients (bottom left) and NSCLC patients (bot-
tom right) with COPD observed under a light microscope at a magnification of × 20. Bars, 100 µm. B, Box-plots depicting 
quantification of GPRC5A immunohistochemical expression represented in (A). Main p value signifies statistical significance 
of reduced GPRC5A expression in the sequential pathogenesis of COPD-associated NSCLC and among the five groups by 
the general linear model and Kruskal–Wallis test. p values signifying the indicated pair wise comparisons among the groups 
were obtained by the Wilcoxon rank sum test. GPRC5A, G-protein coupled receptor family C, group 5, member A; NBE, 
normal bronchial epithelia; NSCLC, non–small-cell lung cancer; COPD, chronic obstructive pulmonary disease; SCC, squa-
mous cell carcinomas; NS, not significant.
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to assess GPRC5A transcript expression in multiple bronchial 
sites (n = 29) as well as in the tumors (n = 6) and uninvolved 
normal lung parenchyma (n = 6) in six NSCLC cases (3 SCCs 
and 3 adenocarcinomas). Quantitative real-time PCR analysis 
demonstrated progressively reduced GPRC5A expression from 
normal uninvolved lung parenchyma (relative quantification 
[RQ] mean, 4.18 ± 0.62; median, 4.16; minimum, 3.51; maxi-
mum, 5.04) to histologically normal and adjacent bronchial epi-
thelia (RQ mean, 3.12 ± 1.94; median, 2.86,; minimum, 0.59; 
maximum, 10.12) to NSCLC tumors (RQ mean, 1.35 ± 0.71; 
median 1.31; minimum 0.24; maximum 2.30), which exhibited 
on an average the lowest expression of the gene (Fig. 3A and B) 
(p = 0.03). These findings suggest that GPRC5A expression is 
reduced in the smoking-injured field cancerization in NSCLC 
highlighting a potentially strong implication of this tumor sup-
pressor in the pathogenesis of this malignancy.
DISCUSSION
In this study, we assessed the expression of GPRC5A, 
which we had found to exhibit lung-specific tumor-suppres-
sor properties in mice,15,16,19 in human NSCLC histological 
tissue specimens, as well as in NBE from COPD and lung 
adenocarcinoma and SCC patients. We found that the protein 
product of human GPRC5A was lower in lung tumors com-
pared with uninvolved histologically NBE, and was signifi-
cantly associated with adenocarcinoma histology. GPRC5A 
airway expression seemed to exhibit a progressive decrease in 
the field cancerization of COPD-related NSCLC with highest 
expression in bronchial epithelia obtained from disease-free 
individuals, intermediate immunoreactivity in normal epithe-
lia from cancer-free COPD patients, and lowest in normal epi-
thelia from patients with both COPD and adenocarcinoma and 
SCC histologies. Furthermore, GPRC5A transcript expression 
was also lower in histologically NBE as well as in adjacent 
and corresponding smoker NSCLC tumors, irrespective of 
COPD status, compared with uninvolved normal lung sugges-
tive of a field cancerization-mediated expression modulation 
of this G-protein coupled receptor. In light of the relevance 
of the field cancerization phenomenon to NSCLC pathogen-
esis,5–7,20,21 our findings pinpoint to a potential tumor-suppres-
sive role, similar to that established in mice, of GPRC5A in 
the sequential development of human NSCLC, in particular 
those associated with inflammatory chronic obstructive dis-
ease. NSCLC and COPD are both mainly attributable to ciga-
rette smoke9,10,13 and are leading causes of deaths in the United 
States and worldwide.1,2,11 Given that COPD is a major risk 
factor for lung cancer and shares various pathogenic features 
with lung tumors,9,10,22–25 better molecular markers are needed 
to identify which COPD patients will continue to develop lung 
malignancies.11 Thus, the results herein raise the intriguing 
possibility that GPRC5A loss may be a useful biomarker in 
assessing the risk of NSCLC development in COPD patients.
COPD and infections as well as inflammatory disorders 
of the respiratory tract may be linked to an increased 
risk of lung cancer.26,27 We have previously demonstrated 
significantly increased macrophage infiltration into lungs of 
Gprc5a-knockout mice along with their direct association 
with adenocarcinomas, which was accompanied by higher 
constitutive levels of proinflammatory cytokines and 
chemokines and increased susceptibility to stimulation of 
nuclear factor-kappa B (NF-κB) activation in vivo.15 We also 
showed that loss of Gprc5a-mediated activation of NF-κB 
was causally linked to macrophage recruitment and enhanced 
inflammation toward the creation of a tumor-promoting 
microenvironment.15 It is noteworthy that lungs of patients 
with severe COPD exhibit macrophage/CD8+ T cell and 
neutrophil infiltration based on histopathological studies and 
bronchial-biopsies.28 Moreover, it is worthwhile to mention 
that we attempted to statistically assess the association 
between expression of GPRC5A and that of NF-κB (nuclear 
p65 immunoreactivity) in NSCLCs and found a significant 
FIGURE 3.  Decreased GPRC5A mRNA expression 
in histologically NBE and corresponding NSCLC 
tumors from resected specimens compared with 
matched uninvolved normal lung. Total RNA was 
isolated from brushings of NBE and frozen sec-
tions of matched NSCLC (T) and uninvolved NL 
parenchyma obtained from resected lobectomy or 
pneumonectomy specimens performed on smoker 
early-stage patients. A, GPRC5A expression was 
analyzed in all samples (in triplicates) by QRTPCR 
and normalized against that of ACTB to yield a 
relative expression by the 2−△△CT method depicted 
in the graphs. NSCLC tumors (squamous cell 
carcinoma, cases 1–3, and adenocarcinomas, cases 
4–6), uninvolved NL parenchyma and bronchial 
structures are labeled by the indicated colors. B, 
GPRC5A transcript expression among uninvolved 
NL tissue, NBE, and NSCLC tumors was assessed 
statistically by repeated measures analysis. NBE, 
normal bronchial epithelia; NSCLC, non–small-cell 
lung cancer; NL, normal lung; CT, comparative 
cycle threshold method.; QRTPCR, quantitative 
real-time polymerase chain reaction.
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inverse correlation between both proteins in particular 
in adenocarcinomas (data not shown). In addition, it was 
recently shown that the incidence of hyperplastic lesions in 
lungs of Gprc5a-knockout mice was increased after exposure 
to nontypeable Haemophilus influenzae.29 Notably, bacterial 
colonization, particularly with nontypeable Haemophilus 
influenzae, has been implicated as a cause of airway 
inflammation in COPD besides cigarette smoke.30 In this 
context, the commonalities between inflammatory-mediated 
and histopathological mechanisms in Gprc5a-knockout mice 
and those evident in lungs of COPD patients along with our 
current findings on reduced GPRC5A expression in normal 
cells from COPD patients pinpoint to a tumor-suppressive role 
of this gene in COPD-associated human lung tumorigenesis.
We previously cloned the retinoid-regulated mGprc5a/
hGPRC5A and found that it was preferentially expressed in fetal 
and adult mouse and human lung tissue compared with nor-
mal specimens from other anatomically distinct organs.31 The 
functional relevance of this lung-specific expression was high-
lighted by our earlier study demonstrating spontaneous devel-
opment of adenomas and adenocarcinomas in Gprc5a-nockout 
mice, which was not observed in wild-type littermates. In addi-
tion, spontaneous tumor development in Gprc5a-knockout 
mice was characterized by late tumor onset (12–16-month-old 
mice) and low multiplicity.16 Notably, we reported that expo-
sure to the tobacco-specific carcinogen 4-(methylnitrosamino)-
1-(3-pyridyl)-1-butanone (nicotine-derived nitrosamine ketone) 
augmented tumorigenesis evidenced by 6-month earlier devel-
opment of lesions, two- to fourfold increased tumor incidence 
and multiplicity, as well as a dramatic increase in lesion size.19 
It is worthy to note that, in this study, we found significantly 
reduced expression of GPRC5A in human smoking-injured 
histologically NBE adjacent to lung tumors and in the local-
ized field cancerization of smoker NSCLC patients, compared 
with uninvolved normal lung. Moreover, reduced GPRC5A 
expression was concomitant among airways and correspond-
ing NSCLC compared with matched normal lung tissue. It is 
plausible to assume that smoking-mediated reduced airway 
expression of GPRC5A in patients may explain our previous 
observations on augmented tumorigenesis in Gprc5a-knockout 
mice after exposure to tobacco carcinogens. Because COPD is 
causally linked to smoking,9–11,22,23 it cannot be neglected that 
reduced GPRC5A expression in NBE from COPD patients 
may be because of the molecular impact of smoking on the 
airway transcriptome. However, it is important to mention 
that we found significantly decreased GPRC5A expression in 
normal epithelia from COPD patients compared with epithe-
lia obtained from disease-free smokers. Moreover, GPRC5A 
expression was further decreased and lowest in normal airway 
epithelia from COPD patients with NSCLC compared with 
those from cancer-free COPD patients. Thus in this context, 
our findings raise the possibility that GPRC5A expression may 
be impacted by cigarette smoking and may be both a cause and 
consequence of increased inflammation in tumor-promoting 
microenvironment in the lung as well as NSCLC development, 
which may be better delineated in future warranted studies.
Our group has previously shown that human lung and 
head and neck cancer cell lines exhibit reduced GPRC5A 
expression compared with their normal counterparts.31 It is 
worthwhile to mention that treatment of cancer cells with 
all-trans retinoic acid restored GPRC5A expression in cells 
devoid of the tumor suppressor in part by a retinoic acid 
receptor-dependent manner.31,32 In addition and in a sepa-
rate study, we have previously noted reduced retinoic acid 
receptor beta (RARβ) in approximately 50% of adenocar-
cinomas and SCCs as well as loss of RARγ and retinoid X 
receptorβ in a significant fraction of the tumors.33 Moreover, 
RARβ expression is decreased in bronchial epithelia and 
preneoplastic lesions representing the sequence of lung SCC 
pathogenesis.34 More recently, we demonstrated, using gene 
expression profiling, that loss of murine Gprc5a in lung epi-
thelial cells reduced expression of markers of squamous dif-
ferentiation concomitantly with an increase in mediators of 
the inflammatory process (e.g., NF-κB signaling). In light 
of the biological connection between retinoid signaling and 
GPRC5A expression as well as our current findings in this 
revised article on the significant reduced expression of the 
tumor suppressor in NBE of COPD patients including those 
with NSCLC, it is plausible to suggest that retinoid signal-
ing may be aberrantly regulated in pathogenesis of COPD-
associated NSCLC. It is important to note that retinoids are 
currently being tested for their lung regenerative properties 
and effects in patients with COPD.35
In conclusion, we report herein decreased expression of 
GPRC5A in human NSCLC tissue compared with uninvolved 
NBE and in the field cancerization of smoker NSCLCs pin-
pointing to a tumor-suppressor role of this G-protein coupled 
receptor in the pathogenesis of this leading cause of cancer-
related deaths. Moreover, our findings highlight a progressive 
decrease in GPRC5A expression in the sequential pathogen-
esis of NSCLCs arising in COPD patients, warranting future 
studies, including the analysis of lung cancer preneoplastic 
lesions, to assess the potential of the utility of this gene as a 
biomarker for lung cancer risk in COPD patients.
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